@EricTopol: The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the mo…
Summary
Eric Topol highlights the remarkable progress in cancer immunotherapy, with vaccines achieving cures or remissions in refractory cancers like pancreatic, melanoma, glioblastoma, renal, and triple-negative breast cancer, and directs readers to his Ground Truths newsletter for more.
View Cached Full Text
Cached at: 05/29/26, 01:31 AM
The ramp up of cancer immunotherapy is remarkable. Now we’re seeing vaccines achieve some cures or remissions in the most refractory cancers: pancreatic, melanoma, glioblastoma, renal, triple-negative breast cancer. ✓ out the new Ground Truths (link in profile) https://t.co/8PE5nOMfj1
Similar Articles
@EricTopol: Big progress vs cancer, folks. The kind of event curves from randomized trials that we've not seen before for a couple …
Big progress against two of the most deadly cancers reported from randomized trials, as highlighted by Eric Topol during the ASCO conference.
@YannickBuccella: The newer generation cancer vaccines aren't like the HPV shot (that prevents a virus). These are therapeutic, they trea…
The article discusses the advancement of therapeutic cancer vaccines using personalized mRNA technology, highlighting recent positive Phase 3 results for melanoma and ongoing trials for other cancers, with potential approvals expected by 2027.
@WSJ: An experimental cancer vaccine kept melanoma from coming back. It’s the first successful late-stage mRNA study validati…
An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.
Moderna stock, $MRNA , surges over +110% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.
Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine, which reduced melanoma recurrence, causing Moderna stock to surge by over 110%.
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.